No Data
Express News | SpringWorks Therapeutics Inc : JP Morgan Cuts Target Price to $64 From $77
GSK, SpringWorks End Collaboration Agreement
Express News | SpringWorks Therapeutics Inc - Termination of License Deal Does Not Trigger Any Payment Obligations on Part of Co/Any Other Material Wind-Down Costs
Express News | SpringWorks Therapeutics Inc - Co Expects That GSK Will Continue Ongoing Clinical Trials Under License Agreement
Express News | SpringWorks Therapeutics Inc - Termination Does Not Affect Co's Rights to Continue Developing or Commercializing Its Products or Product Candidates
Express News | SpringWorks Therapeutics:Deal Termination Between Co & Glaxosmithkline Intellectual Property Development Effective 180 Days After Notice Receipt